Post Marketing Surveillance Study on Emselex After Launch in Germany

Bayer

Status: Completed

Conditions: Overactive Bladder

Treatments: Drug: Darifenacin, Emselex (BAY79-4998)

Study type: Observational

Funder types: Industry

Identifiers

NCT00786448

EX0501DE

12245

Details and patient eligibility

About

• Data are obtained of Emselex in routine treatment of Overactive Bladder. The general objectives are to evaluate the product safety, compatibility, efficacy and patient acceptance.

Enrollment: 5,821 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who are treated with Emselex for Overactive Bladder

Exclusion criteria

• Exclusion criteria are the contraindications as specified in the German product information

Trial design

5,821 participants in 1 patient group

Group 1

Treatment:

Drug: Darifenacin, Emselex (BAY79-4998)